Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression

Min-Soo Lee, Byung-Joo Ham, Baik Seok Kee, Jung B. Kim, Byeong Kil Yeon, Kang Seob Oh, Byoung Hoon Oh, Chul Lee, Han Yong Jung, Ik Seung Chee, Byeong Moo Choe, In H. Paik

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Object: To compare efficacy and safety of milnacipran and fluoxetine in a population of Korean patients with major depression. Research design and methods: The design was a multi-centre, randomised, comparative clinical study. Patients with major depression (DSM-IV diagnostic criteria) scoring over 17 points on the 17-item Hamilton Depression Scale (HAM-D) and over 21 points on the Montgomery-Asberg Depression Rating Scale (MADRS) were recruited and randomised to receive milnacipran (50 mg/ day increasing after 1 week to 100 mg/day) or fluoxetine (20 mg/day) for 6 weeks. All previous medication was stopped at least 7 days before entry into the study. Patients were evaluated (HAM-D, MADRS and clinical global impression scale, CGI) at baseline and after 1,2,4 and 6 weeks of treatment. All adverse events which developed during the study period were recorded. Results: 70 patients (milnacipran 39; fluoxetine 31) were included in the study. Total score on both HAM-D, MADRS and CGI decreased significantly in both groups after 1 week and continued to decrease throughout the study. There was no significant difference between the two groups for any measurement at any time point. Both antidepressants were well tolerated. In the milnacipran group, 13 patients reported 28 adverse reactions, and in the fluoxetine group 11 patients reported 18 adverse reactions. Two patients discontinued due to adverse events in the milnacipran group and three in the fluoxetine group. There were no clinically significant modifications in vital signs, routine blood laboratory tests, biochemistry or ECG throughout the study. Nausea and headache were the most frequently reported adverse events with milnacipran while digestive disturbances, diarrhoea and insomnia were more common with fluoxetine. Conclusion: Milnacipran, like fluoxetine, was found to be effective and well tolerated for the treatment of major depression in this population of depressed Korean patients. Principal limitations of the study were its open design, its small sample size and its relatively short duration.

Original languageEnglish
Pages (from-to)1369-1375
Number of pages7
JournalCurrent Medical Research and Opinion
Volume21
Issue number9
DOIs
Publication statusPublished - 2005 Sep 1

Fingerprint

Fluoxetine
Safety
Depression
milnacipran
Vital Signs
Sleep Initiation and Maintenance Disorders
Hematologic Tests
Diagnostic and Statistical Manual of Mental Disorders
Biochemistry
Sample Size
Nausea
Antidepressive Agents
Population
Headache
Diarrhea
Electrocardiography
Research Design
Therapeutics

Keywords

  • Antidepressant efficacy
  • Fluoxetine
  • Korean ptients
  • Milnacipran
  • Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. / Lee, Min-Soo; Ham, Byung-Joo; Kee, Baik Seok; Kim, Jung B.; Yeon, Byeong Kil; Oh, Kang Seob; Oh, Byoung Hoon; Lee, Chul; Jung, Han Yong; Chee, Ik Seung; Choe, Byeong Moo; Paik, In H.

In: Current Medical Research and Opinion, Vol. 21, No. 9, 01.09.2005, p. 1369-1375.

Research output: Contribution to journalArticle

Lee, M-S, Ham, B-J, Kee, BS, Kim, JB, Yeon, BK, Oh, KS, Oh, BH, Lee, C, Jung, HY, Chee, IS, Choe, BM & Paik, IH 2005, 'Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression', Current Medical Research and Opinion, vol. 21, no. 9, pp. 1369-1375. https://doi.org/10.1185/030079905X59166
Lee, Min-Soo ; Ham, Byung-Joo ; Kee, Baik Seok ; Kim, Jung B. ; Yeon, Byeong Kil ; Oh, Kang Seob ; Oh, Byoung Hoon ; Lee, Chul ; Jung, Han Yong ; Chee, Ik Seung ; Choe, Byeong Moo ; Paik, In H. / Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. In: Current Medical Research and Opinion. 2005 ; Vol. 21, No. 9. pp. 1369-1375.
@article{8e31a5122d564e53afb0c4484255b5c1,
title = "Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression",
abstract = "Object: To compare efficacy and safety of milnacipran and fluoxetine in a population of Korean patients with major depression. Research design and methods: The design was a multi-centre, randomised, comparative clinical study. Patients with major depression (DSM-IV diagnostic criteria) scoring over 17 points on the 17-item Hamilton Depression Scale (HAM-D) and over 21 points on the Montgomery-Asberg Depression Rating Scale (MADRS) were recruited and randomised to receive milnacipran (50 mg/ day increasing after 1 week to 100 mg/day) or fluoxetine (20 mg/day) for 6 weeks. All previous medication was stopped at least 7 days before entry into the study. Patients were evaluated (HAM-D, MADRS and clinical global impression scale, CGI) at baseline and after 1,2,4 and 6 weeks of treatment. All adverse events which developed during the study period were recorded. Results: 70 patients (milnacipran 39; fluoxetine 31) were included in the study. Total score on both HAM-D, MADRS and CGI decreased significantly in both groups after 1 week and continued to decrease throughout the study. There was no significant difference between the two groups for any measurement at any time point. Both antidepressants were well tolerated. In the milnacipran group, 13 patients reported 28 adverse reactions, and in the fluoxetine group 11 patients reported 18 adverse reactions. Two patients discontinued due to adverse events in the milnacipran group and three in the fluoxetine group. There were no clinically significant modifications in vital signs, routine blood laboratory tests, biochemistry or ECG throughout the study. Nausea and headache were the most frequently reported adverse events with milnacipran while digestive disturbances, diarrhoea and insomnia were more common with fluoxetine. Conclusion: Milnacipran, like fluoxetine, was found to be effective and well tolerated for the treatment of major depression in this population of depressed Korean patients. Principal limitations of the study were its open design, its small sample size and its relatively short duration.",
keywords = "Antidepressant efficacy, Fluoxetine, Korean ptients, Milnacipran, Safety",
author = "Min-Soo Lee and Byung-Joo Ham and Kee, {Baik Seok} and Kim, {Jung B.} and Yeon, {Byeong Kil} and Oh, {Kang Seob} and Oh, {Byoung Hoon} and Chul Lee and Jung, {Han Yong} and Chee, {Ik Seung} and Choe, {Byeong Moo} and Paik, {In H.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1185/030079905X59166",
language = "English",
volume = "21",
pages = "1369--1375",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression

AU - Lee, Min-Soo

AU - Ham, Byung-Joo

AU - Kee, Baik Seok

AU - Kim, Jung B.

AU - Yeon, Byeong Kil

AU - Oh, Kang Seob

AU - Oh, Byoung Hoon

AU - Lee, Chul

AU - Jung, Han Yong

AU - Chee, Ik Seung

AU - Choe, Byeong Moo

AU - Paik, In H.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Object: To compare efficacy and safety of milnacipran and fluoxetine in a population of Korean patients with major depression. Research design and methods: The design was a multi-centre, randomised, comparative clinical study. Patients with major depression (DSM-IV diagnostic criteria) scoring over 17 points on the 17-item Hamilton Depression Scale (HAM-D) and over 21 points on the Montgomery-Asberg Depression Rating Scale (MADRS) were recruited and randomised to receive milnacipran (50 mg/ day increasing after 1 week to 100 mg/day) or fluoxetine (20 mg/day) for 6 weeks. All previous medication was stopped at least 7 days before entry into the study. Patients were evaluated (HAM-D, MADRS and clinical global impression scale, CGI) at baseline and after 1,2,4 and 6 weeks of treatment. All adverse events which developed during the study period were recorded. Results: 70 patients (milnacipran 39; fluoxetine 31) were included in the study. Total score on both HAM-D, MADRS and CGI decreased significantly in both groups after 1 week and continued to decrease throughout the study. There was no significant difference between the two groups for any measurement at any time point. Both antidepressants were well tolerated. In the milnacipran group, 13 patients reported 28 adverse reactions, and in the fluoxetine group 11 patients reported 18 adverse reactions. Two patients discontinued due to adverse events in the milnacipran group and three in the fluoxetine group. There were no clinically significant modifications in vital signs, routine blood laboratory tests, biochemistry or ECG throughout the study. Nausea and headache were the most frequently reported adverse events with milnacipran while digestive disturbances, diarrhoea and insomnia were more common with fluoxetine. Conclusion: Milnacipran, like fluoxetine, was found to be effective and well tolerated for the treatment of major depression in this population of depressed Korean patients. Principal limitations of the study were its open design, its small sample size and its relatively short duration.

AB - Object: To compare efficacy and safety of milnacipran and fluoxetine in a population of Korean patients with major depression. Research design and methods: The design was a multi-centre, randomised, comparative clinical study. Patients with major depression (DSM-IV diagnostic criteria) scoring over 17 points on the 17-item Hamilton Depression Scale (HAM-D) and over 21 points on the Montgomery-Asberg Depression Rating Scale (MADRS) were recruited and randomised to receive milnacipran (50 mg/ day increasing after 1 week to 100 mg/day) or fluoxetine (20 mg/day) for 6 weeks. All previous medication was stopped at least 7 days before entry into the study. Patients were evaluated (HAM-D, MADRS and clinical global impression scale, CGI) at baseline and after 1,2,4 and 6 weeks of treatment. All adverse events which developed during the study period were recorded. Results: 70 patients (milnacipran 39; fluoxetine 31) were included in the study. Total score on both HAM-D, MADRS and CGI decreased significantly in both groups after 1 week and continued to decrease throughout the study. There was no significant difference between the two groups for any measurement at any time point. Both antidepressants were well tolerated. In the milnacipran group, 13 patients reported 28 adverse reactions, and in the fluoxetine group 11 patients reported 18 adverse reactions. Two patients discontinued due to adverse events in the milnacipran group and three in the fluoxetine group. There were no clinically significant modifications in vital signs, routine blood laboratory tests, biochemistry or ECG throughout the study. Nausea and headache were the most frequently reported adverse events with milnacipran while digestive disturbances, diarrhoea and insomnia were more common with fluoxetine. Conclusion: Milnacipran, like fluoxetine, was found to be effective and well tolerated for the treatment of major depression in this population of depressed Korean patients. Principal limitations of the study were its open design, its small sample size and its relatively short duration.

KW - Antidepressant efficacy

KW - Fluoxetine

KW - Korean ptients

KW - Milnacipran

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=25444432307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444432307&partnerID=8YFLogxK

U2 - 10.1185/030079905X59166

DO - 10.1185/030079905X59166

M3 - Article

VL - 21

SP - 1369

EP - 1375

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 9

ER -